TellBio
tellbio.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$11M
5 rounds on record
Latest round
$1.2M
Venture round · Jun 2024 · 2 yr ago
Team
51-200
employees, estimated range
Backers
1
Crocker Ventures
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 21, 2024
Raised a round Venture round $1.2M · SEC Form D
Feb 29, 2024
Launched TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer · br.advfn.com
Oct 4, 2023
Raised a round Venture round $1M · SEC Form D
Feb 24, 2023
Raised a round Venture round $2.3M · SEC Form D
May 10, 2021
Launched TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer · tellbio.com
Mar 11, 2021
Raised a round Venture round $5M · SEC Form D
Sep 30, 2019
Raised a round Venture round $1.5M · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jun 2024 | $1.2M | — | SEC Form D |
| Venture round | Oct 2023 | $1M | — | SEC Form D |
| Venture round | Feb 2023 | $2.3M | — | SEC Form D |
| Venture round | Mar 2021 | $5M | — | SEC Form D |
| Venture round | Sep 2019 | $1.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | TellBio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Richard PetersExecutive Officer, DirectorSEC Form D
Pritesh GandhiExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Crocker Ventures Similar startupsby what they do, their industry and backers
A novel priming approach that increases circulating tumor DNA—improving detection and enabling better clinical decisions without changing…
Clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS).
Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.
Who is Catchwise? Catchwise's goal is to revolutionize the fishing industry with data.
Cloverleaf Bio | Developing a new class of RNA therapeutics to revolutionize cancer therapy.
Juvena Therapeutics is a clinical-stage biotechnology company engineering proteins that human stem cells naturally secrete into…
Overview
TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutics platform, TellDx and TellRx, respectively.
News
TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer
TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer Study Results Support the use of TellDx to Personalize Cancer Care Management Clinical study published in Cancer Discovery Andover, MA., Ja
Read more
Report
10.11582159-8290.CD-25-1483
Andover, MA., January 14, 2026 (GLOBE NEWSWIRE) TellBio, Inc., a medical technology company focused on revolutionizing the management of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces th
Read more
Report
Tellbio's Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223 therapy in prostate cancer -- -- Clinical study publish
Read more
Report
Tellbio's Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
Tellbio's Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223 AR-V7 expression in CTCs isolated with TellDx is an independent negati
Read more
Report
Pro access
Upgrade to see all 16 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Richard Peters
Executive Officer, Director
Pritesh Gandhi
Executive Officer, Director
Gary Crocker
Director
Bernard Peters
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Beverly
United States
HQ
50-200 est. staff
Financials
Total raised
$11M
Latest round
Venture - Series Unknown
Funding rounds
5